BIOX Bioceres Crop Solutions Corp.

NEUTRAL Impact: 4/10 6-K
Horizon weeks Filed Jun 1, 2026 Processed 4d 5h ago SEC 0001104659-26-068690
Notable filing: 6-K
Latest settled — T+1d
BIOX ▲ +2.29% at T+1d
NEUTRAL call ✓ call won +2.29% · α vs SPY +2.15% · entry $0.4800 → $0.4910
Next anchor: T+5d in 3d
Currently $0.4309 · -10.23% from $0.4800 entry
Entry anchored
May 29, 03:59 PM ET
via Databento tick
T+1d
+2.29%
call +2.29% · α +2.15%
$0.4910
settled 3d ago
T+5d
call — · α —
in 3d
T+20d
call — · α —
in 25d
T+60d
call — · α —
in 3mo

Price Chart

Loading chart...

Executive Summary

Bioceres Crop Solutions Corp. subsidiary Rizobacter completed an exchange offer and consent solicitation on ~86% of ~$42.7M in outstanding Series IX and X notes, extending maturities as part of broader liability management. This reduces near-term refinancing risk for a key subsidiary but does not address the parent company's $28M market cap or underlying operational performance.

Actionable Insight

The exchange offer reduces near-term debt maturity pressure at the subsidiary level, a modest credit positive. However, with a $28M market cap and no analyst bullish coverage, the parent company's equity remains highly speculative. Monitor for any parent-level debt restructuring or operational updates in upcoming 20-F filing.

Key Facts

  • Rizobacter completed exchange offer and consent solicitation on May 29, 2026.
  • Participation of ~86% of total outstanding principal amount of Series IX Class A, IX Class B, X Class A, and X Class B notes.
  • Transaction relates to ~US$42.7 million aggregate principal amount of existing notes.
  • Part of Rizobacter's broader liability management and maturity extension efforts.
  • Filing is a 6-K by foreign private issuer Bioceres Crop Solutions Corp. (BIOX).

Financial Impact

~US$42.7 million in notes restructured; 86% participation rate indicates strong creditor support for maturity extension.

debtliquidity

Risk Factors

  • Exchange offer details (new terms, maturity extension length) not disclosed; may involve higher interest costs or dilution.
  • Parent company's small market cap and lack of analyst support suggest limited equity upside from subsidiary-level debt management.
  • Argentine macroeconomic and currency risks for Rizobacter's operations.

Market Snapshot

Exchange
Nasdaq
Sector
Agricultural Chemicals
Analyst Consensus
0% bullish (6 analysts)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001104659-26-068690
Document: 0001104659-26-068690-index-headers.html0001104659-26-068690
Document: 0001104659-26-068690-index.html0001104659-26-068690
Document: 0001104659-26-068690.txt0001104659-26-068690

US Market Status

Market Open — Closes in 8m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access